$FLXN News
Last published 5mo ago
- 5mo agoFLXNFLXN1Jefferies Global Healthcare Conference - FLEXION THERAPEUTICS INCEarnings Call TranscriptsGood morning, everyone. My name is Anthea Lee, part of the SPEC Pharma team at Jefferies. Welcome to our healthcare conference in New York. Really great to have Frank Lee with Pacira Biosciences' CEO, Pacira Sciences, he
- 4y agoFLXNAvilar Therapeutics Appoints Adam Muzikant, PhD, as Chief Business OfficerBusiness WireAvilar Therapeutics, a biopharmaceutical company focused on extracellular protein degradation, today announced the appointment of Adam Muzikant, PhD, as Chief Business Officer. Dr. Muzikant brings 18 years of business development experience creating and
- 4y agoFLXNPCRXPacira BioSciences Completes Acquisition of Flexion Therapeutics and Strengthens Leadership Position in Non-Opioid Pain ManagementGlobeNewswire-- Adds highly complementary ZILRETTA® to Pacira commercial offering -- -- Combined portfolio offers end-to-end non-opioid solutions along the pain pathway -- TAMPA, Fla. and BURLINGTON, Mass., Nov. 19, 2021 (GLOBE NEWSWIRE) -- Pacira BioScience
- 5y agoAZPNDUNEFLXNMDPMoore Kuehn Encourages MDP, DUNE, FLXN, and AZPN Investors to Contact Law FirmPR NewswireNEW YORK, Oct. 15, 2021 /PRNewswire/ -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to sha
- 5y agoAVDLFLXNMGYPTGX+1Thinking about buying stock in Protagonist Therapeutics, Flexion Therapeutics, Avadel Pharmaceuticals, US Well Services, or Magnolia Oil & Gas?PR NewswireNEW YORK, Oct. 11, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PTGX, FLXN, AVDL, USWS, and MGY.
- 5y agoFLXNPCRXPacira BioSciences to Acquire Flexion Therapeutics Further Expanding Leadership Position in Non-Opioid Pain ManagementGlobeNewswire-- Adds highly complementary ZILRETTA® to Pacira commercial offering -- -- Combined portfolio offers end-to-end non-opioid solutions along the pain pathway -- -- Further enhances topline revenue growth; provides attractive potential synergies and
- 5y agoFLXNFlexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireBURLINGTON, Mass., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (NASDAQ:FLXN) today announced equity inducement grants to three new employees consisting of 6,315 restricted stock units. The Compensation Committee of the Board of Directo
- 5y agoFLXNFlexion Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment ConferenceGlobeNewswireBURLINGTON, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (NASDAQ:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in a virtual analyst-led fireside chat at the H.C. Wainwr
- 5y agoFLXNFlexion Therapeutics to Present at the Wells Fargo 2021 Virtual Healthcare ConferenceGlobeNewswireBURLINGTON, Mass., Sept. 03, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (NASDAQ:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the Wells Fargo 2021 V
- 5y agoFLXNFlexion Therapeutics Announces Inclusion of ZILRETTA® in American Academy of Orthopaedic Surgeons (AAOS) Clinical Practice Guidelines for the Management of Osteoarthritis of the KneeGlobeNewswireAAOS finds that ZILRETTA (triamcinolone acetonide extended-release injectable suspension) can improve patient outcomes over immediate-release corticosteroids BURLINGTON, Mass., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (NASDA
- 5y agoFLXNFlexion Therapeutics Announces Expansion of Phase 1b Trial Investigating FX301 for the Management of Post-Operative PainGlobeNewswireInitial findings from proof-of-concept trial in patients undergoing bunionectomy support expansion of the study to include 36 additional patients Data from the trial, including the expansion cohort, anticipated by year-end BURLINGTON, Mass., Aug.
- 5y agoFLXNFlexion Therapeutics Announces Publication of Results from Phase 2 Pharmacokinetics (PK) and Safety Study of ZILRETTA® in Shoulder Osteoarthritis (OA)GlobeNewswireData published in Drugs in R&D confirms extended-release PK profile of ZILRETTA (triamcinolone acetonide extended-release injectable suspension) in patients with shoulder OA Plasma PK data indicate the total and maximal exposure to triamcinolone aceto
- 5y agoFLXNFlexion Therapeutics Reports Second-Quarter 2021 Financial Results and Recent Business HighlightsGlobeNewswireZILRETTA® (triamcinolone acetonide extended-release injectable suspension) net sales were $28.2 million in Q2 2021, reflecting growth of 15% over the previous quarter Net loss in Q2 2021 decreased by $10.4 million (32%), as compared to Q2 2020, duri
- 5y agoFLXNFlexion Therapeutics, inc (FLXN) Q2 2021 Earnings Call TranscriptEarnings Call TranscriptsFLXN earnings call for the period ending December 31, 2020.
- 5y agoFLXNFlexion Therapeutics to Report Second-Quarter 2021 Financial Results on August 4, 2021GlobeNewswireBURLINGTON, Mass., July 29, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (NASDAQ:FLXN) today announced that it will report its second-quarter 2021 financial results after the close of the U.S. financial markets on Wednesday, August 4, 2021 at 4:
- 5y agoFLXNFlexion Therapeutics Announces Appointment of Utpal Koppikar to its Board of DirectorsGlobeNewswireBURLINGTON, Mass., July 12, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (NASDAQ:FLXN) today announced the appointment of Utpal Koppikar, Chief Financial Officer of Atara Biotherapeutics, to its Board of Directors. Mr. Koppikar will serve as the
- 5y agoFLXNFlexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireBURLINGTON, Mass., July 02, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (NASDAQ:FLXN) today announced equity inducement grants to five new employees consisting of 20,440 restricted stock units. The Compensation Committee of the Board of Directo
- 5y agoFLXNFlexion Therapeutics to Present at the 2021 Raymond James Human Health Innovation ConferenceGlobeNewswireBURLINGTON, Mass., June 14, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (NASDAQ:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the 2021 Raymond James
- 5y agoFLXNFlexion Therapeutics Announces Appointment of William T. Andrews, M.D., F.A.C.P., as Chief Medical OfficerGlobeNewswireBURLINGTON, Mass., June 09, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (NASDAQ:FLXN) today announced that William T. Andrews, M.D., F.A.C.P., will join the company as Chief Medical Officer (CMO), effective July 1, 2021. "Will brings an impr
- 5y agoFLXNFlexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireBURLINGTON, Mass., June 04, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (NASDAQ:FLXN) today announced equity inducement grants to five new employees consisting of 8,510 restricted stock units. The Compensation Committee of the Board of Director
- 5y agoFLXNFlexion Therapeutics to Present at the Goldman Sachs 42nd Annual Global Healthcare Virtual ConferenceGlobeNewswireBURLINGTON, Mass., June 02, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (NASDAQ:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the Goldman Sachs 42nd
- 5y agoFLXNFlexion Therapeutics to Present at the RBC Capital Markets 2021 Virtual Global Healthcare ConferenceGlobeNewswireBURLINGTON, Mass., May 13, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (NASDAQ:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the RBC Capital Markets
- 5y agoFLXNFlexion Therapeutics Reports First-Quarter 2021 Financial Results and Recent Business UpdatesGlobeNewswireFlexion reported ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) net sales of $24.6 million David Arkowitz, CFO, stepping down effective May 31,2021, and will be succeeded by Fred Driscoll New data presented at ASGCT ind
- 5y agoFLXNFlexion Therapeutics, Inc. to Host Earnings CallACCESS NewswireNEW YORK, NY / ACCESSWIRE / May 12, 2021 / Flexion Therapeutics, Inc. (NASDAQ:FLXN) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on May 12, 2021 at 4:30 PM Eastern Time. To listen to the event live or ac
- 5y agoFLXNFlexion Therapeutics Inc (FLXN) Q1 2021 Earnings Call TranscriptEarnings Call TranscriptsFLXN earnings call for the period ending March 31, 2021.
- 5y agoFLXNFlexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireBURLINGTON, Mass., May 07, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (NASDAQ:FLXN) today announced equity inducement grants to eight new employees consisting of 18,200 restricted stock units. The Compensation Committee of the Board of Directo
- 5y agoFLXNFlexion Therapeutics to Report First-Quarter 2021 Financial Results on May 12, 2021GlobeNewswireBURLINGTON, Mass., May 05, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (NASDAQ:FLXN) today announced that it will report its first-quarter 2021 financial results after the close of the U.S. financial markets on Wednesday, May 12, 2021. A liv
- 5y agoFLXNFlexion Therapeutics Announces Presentation of Preliminary FX201 Clinical Data at the Upcoming 2021 American Society of Gene & Cell Therapy (ASGCT) Annual MeetingGlobeNewswireFindings from a Phase 1 single ascending dose trial indicate the low dose of FX201, an intra-articular gene therapy candidate for osteoarthritis (OA), was generally well-tolerated Two of five patients (40%) treated with FX201 in the low-dose, single as
- 5y agoFLXNFlexion Therapeutics Inc (FLXN) Q1 2021 Earnings Call TranscriptEarnings Call TranscriptsFLXN earnings call for the period ending March 31, 2021.
- 5y agoFLXNFlexion Therapeutics Announces Preliminary First-Quarter 2021 Revenue and Provides Financial Guidance for 2021GlobeNewswireFirst-quarter ZILRETTA® net sales estimated to be approximately $24.6 million2021 full-year ZILRETTA net sales anticipated to be in the range of $120 million to $130 million and total operating...
- 5y agoFLXNFlexion Therapeutics to Present at the Needham 20th Annual Virtual Healthcare ConferenceGlobeNewswireBURLINGTON, Mass., April 08, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in...
- 5y agoFLXNFlexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireBURLINGTON, Mass., April 02, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to five new employees consisting of 60,880 restricted stock...
- 5y agoFLXNFlexion Therapeutics Announces First Patient Treated in FX301 Phase 1b Trial for Management of Post-Operative PainGlobeNewswireFX301 is a locally administered NaV1.7 inhibitor (funapide) formulated for extended release in a proprietary thermosensitive hydrogelProof-of-concept trial will evaluate safety and tolerability of...
- 5y agoFLXNFlexion Therapeutics to Present at the Oppenheimer 31st Annual Virtual Healthcare ConferenceGlobeNewswireBURLINGTON, Mass., March 15, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in...
- 5y agoFLXNFlexion Therapeutics Inc (FLXN) Q4 2020 Earnings Call TranscriptEarnings Call TranscriptsFLXN earnings call for the period ending December 31, 2020.
- 5y agoFLXNFlexion Therapeutics Reports Fourth-Quarter and Full-Year 2020 Financial ResultsGlobeNewswireCompany reported ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) net sales of $85.6 million for full-year 2020 representing 17% growth over 2019First patient treated in high...
- 5y agoFLXNFlexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireBURLINGTON, Mass., March 05, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to four new employees consisting of 14,565 restricted stock...
- 5y agoFLXNFlexion Therapeutics to Report Fourth-Quarter and Full-Year 2020 Financial Results on March 10, 2021GlobeNewswireBURLINGTON, Mass., March 03, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it will report its fourth-quarter and full-year 2020 financial results after the...
- 5y agoFLXNFlexion Therapeutics Announces FDA Clearance of Investigational New Drug Application for FX301, a Novel Formulation of a Locally Administered NaV1.7 Inhibitor for Post-Operative PainGlobeNewswireFX301 combines NaV1.7 inhibitor (funapide) with a proprietary thermosensitive hydrogel to facilitate administration as a peripheral analgesic nerve blockFX301 may provide 3 to 5 days of non-opioid...
- 5y agoFLXNFlexion Therapeutics to Present at the 42nd Annual Raymond James Virtual Institutional Investors ConferenceGlobeNewswireBURLINGTON, Mass., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in...
- 5y agoFLXNFlexion Therapeutics to Advance Investigational Gene Therapy FX201 into High Dose Cohort of Phase 1 Clinical Trial in Knee Osteoarthritis and Expand Low and Mid Dose Treatment GroupsGlobeNewswireFirst-in-human single ascending dose trial advances to high dose cohort following positive Data Monitoring Committee review of mid dose safety dataCompany to expand FX201 low dose and mid dose cohorts...
- 5y agoFLXNNational Basketball Retired Players Association, Sheryl Swoopes and Flexion Therapeutics Announce Partnership to Raise Awareness of ZILRETTA®GlobeNewswireCHICAGO and BURLINGTON, Mass., Feb. 01, 2021 (GLOBE NEWSWIRE) -- The National Basketball Retired Players Association (NBRPA) and Flexion Therapeutics Inc. today announced a new partnership to raise...
- 5y agoFLXNFlexion Therapeutics Announces Preliminary, Unaudited Fourth-Quarter and Full-Year 2020 ResultsGlobeNewswireFourth-quarter 2020 ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) net sales estimated to be approximately $26.3 millionFull-year 2020 net sales estimated to be...
- 5y agoFLXNFlexion Therapeutics to Present at the ICR | Westwicke Investment ConferenceGlobeNewswireBURLINGTON, Mass., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in...
- 5y agoFLXNFlexion Therapeutics to Present at the Needham Virtual Epilepsy and Pain Specialty CNS Therapeutics ConferenceGlobeNewswireBURLINGTON, Mass., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in...
- 5y agoFLXNFlexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireBURLINGTON, Mass., Dec. 04, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to six new employees consisting of 22,798 restricted stock...
- 6y agoFLXNFlexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireBURLINGTON, Mass., Nov. 06, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to two new employees consisting of 3,315 restricted stock...
- 6y agoFLXNFlexion Therapeutics to Present at the 29th Annual Credit Suisse Virtual Healthcare ConferenceGlobeNewswireBURLINGTON, Mass., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in...
- 6y agoFLXNFlexion Therapeutics Reports Third-Quarter 2020 Financial Results and Recent Business HighlightsGlobeNewswireCompany reported ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) net sales of $23.7 million in third quarter 2020 BURLINGTON, Mass., Nov. 04, 2020 (GLOBE NEWSWIRE) --...
- 6y agoFLXNFlexion Therapeutics to Report Third-Quarter 2020 Financial Results on November 4, 2020GlobeNewswireBURLINGTON, Mass., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it will report its third-quarter 2020 financial results after the close of the U.S....